7/15/20
Dynavax the manufacturer of Heplisav-B, the 2 dose only hepatitis b vaccine is joining forces with Medicago to develop an adjuvanted COVID-19 vaccine. Heplisav-B is designed to prevent hepatitis B in patients 18 years of age and older with only 2 doses. It is this impressive immune response generated by the adjuvant CpG 1018 in Heplisav-B that will be combined with Medicago’s Corona Virus-Like Particle CoVLP.